Despite important advances in drug development, effective and convenient drug delivery remains an unmet challenge. Many patients suffer from side effects associated with inconsistent levels of medication in the blood and struggle with compliance.
Compliance with the principles of the UK Corporate Governance Code remains high; however, when boards choose not to follow provisions too many explanations are of poor quality.
